Cullinan Therapeutics hires Mary Kay Fenton as CFO; $495k salary, 200k-share option grant

Cullinan Therapeutics, Inc.

Mary Kay Fenton appointed CFO effective April 29, 2024; previously CFO of Talaris Therapeutics.
Annual base salary set at $495,000; target annual bonus of 40% of base salary.
Received option to purchase 200,000 shares vesting over 4 years (25% one-year cliff).
Severance: 9 months base salary plus prorated bonus if terminated without cause or for good reason outside CIC period.
No familial relationship with directors/officers; at-will employment.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mary Kay Fenton

Chief Financial Officer

CGEM · Cullinan Therapeutics, Inc.

Effective: 2024-04-29
Filed: April 29, 2024, 7:59 PM ET

On April 29, 2024, Cullinan Therapeutics, Inc. (the “Company”) announced the hiring and appointment of Mary Kay Fenton as the Company’s Chief Financial Officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Mary Kay Fenton was appointed as Chief Financial Officer at Cullinan Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On April 29, 2024, Cullinan Therapeutics, Inc. (the “Company”) announced the hiring and appointment of Mary Kay Fenton as the Company’s Chief Financial Officer, effective immediately.

View on SEC.gov

Cullinan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-049436

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.